Countries covered: Global
With cardiovascular disease still the leading cause of morbidity and mortality worldwide, the challenge now is to develop increasingly sensitive diagnostic modalities, especially in vitro diagnostic tests, that can solve the problem of early diagnosis or detection of predisposing factors. Key drivers are forecast to boost the market for cardiac diagnostics from $14 billion in 2001 to $2.2 billion in 2006, 12% per year.
Theta’s report presents diagnostic modalities for the detection of cardiovascular disease throughout the continuum of disease progression, including congestive heart failure, unstable angina, myocardial infarction, stroke, and other manifestations of cardiovascular disease. The emphasis is on in vitro diagnostic tests, primarily because this is where the major market opportunities lie.
The report covers market trends and issues concerning:
- In vitro diagnostic biomarkers and genetic indicators
- Point-of-care testing
- Bioinformatics
- In vivo diagnostics
For in vitro diagnostics, this report provides information on companies and technologies that will challenge the status quo of traditional cardiovascular disease testing. Specific areas covered are:
- Lipid markers
- Inflammation markers
- Enzymes and proteins
- AMI enzymes
- Procoagulation and thrombolytic markers
- Genetic markers
- Diabetes testing
Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.
Related Reports:
Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
Cardiac Markers Pipeline Technology and Market Forecasts to 2015
Biomarkers- Advanced Technologies and Global Market (2009-2014)
Cardiovascular Monitoring and Diagnostic Devices Clinical Trial Analysis
Cardiac Markers Clinical Trial Analysis
European Markets for Cardiovascular Disease Diagnostic Products
Cardiac Biomarkers
The 2009-2014 World Outlook for Cardiovascular Disease (CVD) Diagnostics
The 2009 Report on Cardiovascular Disease (CVD) Diagnostics: World Market Segmentation by City
Stakeholder Insight: Acute Coronary Syndromes ACS in Europe, what is the best practice?
|
(0 items)
